| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study
|
Hata, Akito
|
|
|
197 |
C |
p.
|
artikel
|
| 2 |
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
|
Planchard, David
|
|
|
197 |
C |
p.
|
artikel
|
| 3 |
CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients’ prognosis treated with chemoimmunotherapy
|
Bai, Zhexin
|
|
|
197 |
C |
p.
|
artikel
|
| 4 |
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS
|
Pang, Jingdan
|
|
|
197 |
C |
p.
|
artikel
|
| 5 |
Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities
|
He, Xue
|
|
|
197 |
C |
p.
|
artikel
|
| 6 |
Contents
|
|
|
|
197 |
C |
p.
|
artikel
|
| 7 |
Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]
|
Bauman, Jessica R.
|
|
|
197 |
C |
p.
|
artikel
|
| 8 |
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
|
Kang, Dong-Won
|
|
|
197 |
C |
p.
|
artikel
|
| 9 |
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma
|
Xu, Duo
|
|
|
197 |
C |
p.
|
artikel
|
| 10 |
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
|
Kato, Yuki
|
|
|
197 |
C |
p.
|
artikel
|
| 11 |
Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods
|
Tabe, Chiori
|
|
|
197 |
C |
p.
|
artikel
|
| 12 |
Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain
|
Teixidor-Vilà, Eduard
|
|
|
197 |
C |
p.
|
artikel
|
| 13 |
MTAP as an emerging biomarker in thoracic malignancies
|
Brune, Magdalena M.
|
|
|
197 |
C |
p.
|
artikel
|
| 14 |
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study
|
Tu, Xueliang
|
|
|
197 |
C |
p.
|
artikel
|
| 15 |
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)
|
Johnson, Melissa
|
|
|
197 |
C |
p.
|
artikel
|
| 16 |
Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy
|
Qiu, Da
|
|
|
197 |
C |
p.
|
artikel
|
| 17 |
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes
|
Bertolaccini, Luca
|
|
|
197 |
C |
p.
|
artikel
|
| 18 |
Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma in situ overlaps with invasive patterns. Proposal for a necessary modified classification of pulmonary adenocarcinomas
|
Filipello, Federica
|
|
|
197 |
C |
p.
|
artikel
|
| 19 |
Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC
|
Snider, Michael
|
|
|
197 |
C |
p.
|
artikel
|
| 20 |
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)
|
Ou, Sai-Hong
|
|
|
197 |
C |
p.
|
artikel
|
| 21 |
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
|
Zwierenga, F.
|
|
|
197 |
C |
p.
|
artikel
|
| 22 |
Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming
|
Chan, Yap-Hang
|
|
|
197 |
C |
p.
|
artikel
|
Tijdschrift beschrijving